ANN ARBOR, MI--(MARKET WIRE)--Oct 1, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX:PP - News), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has submitted a pre-IDE (Investigational Device Exemption) application with the FDA for FreeBound™, Pipex’s novel device for the rapid detection of free copper levels in blood serum.
